Literature DB >> 21317382

A population-based assessment of specialty physician involvement in cancer clinical trials.

Carrie N Klabunde1, Nancy L Keating, Arnold L Potosky, Anita Ambs, Yulei He, Mark C Hornbrook, Patricia A Ganz.   

Abstract

BACKGROUND: Clinical trials are critical for evaluating new cancer therapies, but few adult patients participate in them. Physicians have an important role in facilitating patient participation in clinical trials. We examined the characteristics of specialty physicians who participate in clinical trials by enrolling or referring patients, the types of trials in which they participate, and factors associated with physicians who report greater involvement in clinical trials.
METHODS: We analyzed data from the Cancer Care Outcomes Research and Surveillance Consortium. The study included 1533 specialty physicians who cared for colorectal and lung cancer patients (496 medical oncologists, 228 radiation oncologists, and 809 surgeons) and completed a survey conducted during 2005-2006 (response rate = 61.0%). Descriptive statistics were used to characterize physicians' personal and practice characteristics, and regression models were used to examine associations between these characteristics and physician participation in clinical trials. All statistical tests were two-sided.
RESULTS: A total of 87.8% of medical oncologists, 66.1% of radiation oncologists, and 35.0% of surgeons reported referring or enrolling one or more patients in clinical trials during the previous 12 months. The mean number of patients referred or enrolled by these physicians was 17.2 (95% confidence interval [CI] = 15.5 to 18.9) for medical oncologists, 9.5 (95% CI = 7.7 to 11.3) for radiation oncologists, and 12.2 (95% CI = 9.8 to 14.6) for surgeons (P < .001). Specialty type, involvement in teaching, and affiliation with a Community Clinical Oncology Program (CCOP) and/or a National Cancer Institute-designated cancer center were associated with physician trial participation and enrolling more patients (all Ps < .05). Two-thirds of physicians with a CCOP or National Cancer Institute-designated cancer center affiliation reported participating in trials.
CONCLUSIONS: Features of specialty physicians' practice environments are associated with their trial participation, but many physicians at CCOPs and cancer centers do not participate.

Entities:  

Mesh:

Year:  2011        PMID: 21317382      PMCID: PMC3107589          DOI: 10.1093/jnci/djq549

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  45 in total

1.  To refer or not to refer: Factors that affect primary care provider referral of patients with cancer to clinical treatment trials.

Authors:  Paula R Sherwood; Barbara A Given; Aaron Scholnik; Charles W Given
Journal:  J Cancer Educ       Date:  2004       Impact factor: 2.037

2.  Provider roles in the recruitment of underrepresented populations to cancer clinical trials.

Authors:  Mollie W Howerton; M Chris Gibbons; Charles R Baffi; Tiffany L Gary; Gabriel Y Lai; Shari Bolen; Jon Tilburt; Teerath Peter Tanpitukpongse; Renee F Wilson; Neil R Powe; Eric B Bass; Jean G Ford
Journal:  Cancer       Date:  2007-02-01       Impact factor: 6.860

3.  Revisiting the behavioral model and access to medical care: does it matter?

Authors:  R M Andersen
Journal:  J Health Soc Behav       Date:  1995-03

Review 4.  Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors.

Authors:  Edward J Mills; Dugald Seely; Beth Rachlis; Lauren Griffith; Ping Wu; Kumanan Wilson; Peter Ellis; James R Wright
Journal:  Lancet Oncol       Date:  2006-02       Impact factor: 41.316

5.  How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials.

Authors:  Warren B Sateren; Edward L Trimble; Jeffrey Abrams; Otis Brawley; Nancy Breen; Leslie Ford; Mary McCabe; Richard Kaplan; Malcolm Smith; Richard Ungerleider; Michaele C Christian
Journal:  J Clin Oncol       Date:  2002-04-15       Impact factor: 44.544

6.  Variations in surgeon treatment recommendations for lobectomy in early-stage non-small-cell lung cancer by patient age and comorbidity.

Authors:  Selwyn O Rogers; Stacy W Gray; Mary Beth Landrum; Carrie N Klabunde; Katherine L Kahn; Robert H Fletcher; Steven Clauser; Diana Tisnado; William Doucette; Nancy L Keating
Journal:  Ann Surg Oncol       Date:  2010-02-17       Impact factor: 5.344

7.  Overcoming barriers to cancer clinical trial accrual: impact of a mass media campaign.

Authors:  Ari Umutyan; Christine Chiechi; Laurel A Beckett; Debora A Paterniti; Corinne Turrell; David R Gandara; Sharon W Davis; Ted Wun; Moon S Chen; Primo N Lara
Journal:  Cancer       Date:  2008-01-01       Impact factor: 6.860

Review 8.  Addressing the current challenges of non-small-cell lung cancer clinical trial accrual.

Authors:  Walter J Curran; Joan H Schiller; Allan C Wolkin; Robert L Comis
Journal:  Clin Lung Cancer       Date:  2008-07       Impact factor: 4.785

9.  Central challenges facing the national clinical research enterprise.

Authors:  Nancy S Sung; William F Crowley; Myron Genel; Patricia Salber; Lewis Sandy; Louis M Sherwood; Stephen B Johnson; Veronica Catanese; Hugh Tilson; Kenneth Getz; Elaine L Larson; David Scheinberg; E Albert Reece; Harold Slavkin; Adrian Dobs; Jack Grebb; Rick A Martinez; Allan Korn; David Rimoin
Journal:  JAMA       Date:  2003-03-12       Impact factor: 56.272

10.  Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials.

Authors:  H A Tejeda; S B Green; E L Trimble; L Ford; J L High; R S Ungerleider; M A Friedman; O W Brawley
Journal:  J Natl Cancer Inst       Date:  1996-06-19       Impact factor: 13.506

View more
  38 in total

1.  Update: APOR.

Authors:  Peter H Wiernik
Journal:  Clin Transl Sci       Date:  2011-11-22       Impact factor: 4.689

2.  A Patient Focused Solution for Enrolling Clinical Trials in Rare and Selective Cancer Indications: A Landscape of Haystacks and Needles.

Authors:  Eric B Lynam; Jiin Leaw; Matthew B Wiener
Journal:  Drug Inf J       Date:  2012-07

3.  Recruiting Endometrial Cancer Survivors to Studies Examining Lifestyle Behaviors and Quality of Life: Challenges Faced and Lessons Learned.

Authors:  Alexander R Lucas; Brian C Focht; David E Cohn; Maryanna D Klatt; Janet Buckworth
Journal:  J Cancer Educ       Date:  2018-08       Impact factor: 2.037

4.  Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck.

Authors:  Joshua M Bauml; Ravi Vinnakota; Yeun-Hee Anna Park; Susan E Bates; Tito Fojo; Charu Aggarwal; Sewanti Limaye; Nevena Damjanov; Jessica Di Stefano; Christine Ciunci; Eric M Genden; Juan P Wisnivesky; Rocco Ferrandino; Ronac Mamtani; Corey J Langer; Roger B Cohen; Keith Sigel
Journal:  J Natl Cancer Inst       Date:  2019-05-01       Impact factor: 13.506

5.  AccrualNet: Addressing Low Accrual Via a Knowledge-Based, Community of Practice Platform.

Authors:  Holly A Massett; Linda K Parreco; Rose Mary Padberg; Ellen S Richmond; Marie E Rienzo; Colleen E Ryan Leonard; Whitney Quesenbery; H William Killiam; Lenora E Johnson; David M Dilts
Journal:  J Oncol Pract       Date:  2011-10-21       Impact factor: 3.840

6.  The Effect of Receiving Treatment Within a Clinical Trial Setting on Survival and Quality of Care Perception in Advanced Stage Non-Small Cell Lung Cancer.

Authors:  Taher Abu-Hejleh; Elizabeth A Chrischilles; Thorvardur R Halfdanarson; Christian Simon; Jane F Pendergast; Dingfeng Jiang; Carmen J Smith; Aaron T Porter; Knute D Carter; Robert B Wallace
Journal:  Am J Clin Oncol       Date:  2016-04       Impact factor: 2.339

7.  Improved clinical trial enrollments for uterine leiomyosarcoma patients after gynecologic oncology partnership with a sarcoma center.

Authors:  S E S Lange; J Liu; D R Adkins; M A Powell; B A Van Tine; D G Mutch
Journal:  Gynecol Oncol       Date:  2015-12-21       Impact factor: 5.482

8.  Perceptions and needs of women with metastatic breast cancer: a focus on clinical trials.

Authors:  Zeina A Nahleh; Nancy U Lin; Antonio C Wolff; Fatima Cardoso
Journal:  Breast       Date:  2013-03-25       Impact factor: 4.380

9.  Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience.

Authors:  Otto Metzger-Filho; Evandro de Azambuja; Ian Bradbury; Kamal S Saini; José Bines; Sergio D Simon; Veerle Van Dooren; Gursel Aktan; Kathleen I Pritchard; Antonio C Wolff; Ian Smith; Christian Jackisch; Istvan Lang; Michael Untch; Frances Boyle; Binghe Xu; Jose Baselga; Edith A Perez; Martine Piccart-Gebhart
Journal:  Oncologist       Date:  2013-01-28

10.  Patient Navigation As a Model to Increase Participation of African Americans in Cancer Clinical Trials.

Authors:  Mona N Fouad; Aras Acemgil; Sejong Bae; Andres Forero; Nedra Lisovicz; Michelle Y Martin; Gabriela R Oates; Edward E Partridge; Selwyn M Vickers
Journal:  J Oncol Pract       Date:  2016-05-17       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.